BMO starts 'show-me story' Integra LifeSciences with a Market Perform
As previously reported, BMO Capital initiated coverage of Integra LifeSciences with a Market Perform rating and $19 price target. While early signs of recovery - including a Q1 beat and record Integra Skin production - are "encouraging," the firm believes three years of guidance cuts have left Integra "a show-me story," the analyst tells investors.
As previously reported, BMO Capital initiated coverage of Integra LifeSciences with a Market Perform rating and $19 price target. While early signs of recovery - including a Q1 beat and record Integra Skin production - are "encouraging," the firm believes three years of guidance cuts have left Integra "a show-me story," the analyst tells investors.